drugset / Trial / NCT00245960

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

NCT00245960

Phase 4 Completed 752 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.

Timeline

Start
2005-12-27
Primary completion
2008-03-29
Completion
2008-03-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications